--News Direct--
McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today announces a Community-Based Partnership (CBP) with the David R. Metcalf Invisible Wounds Foundation, a non-profit organization that advances brain health care for active duty military and veterans by addressing traumatic brain injury (TBI) and suicide prevention among Naval Special Warfare and special operations forces.
Between 2001 and 2021, over 30,000 active-duty personnel and veterans who served in the military after 9/11 died by suicide, compared to the 7,057 service members who died in combat during that same 20-year period. David Metcalf was a Navy SEAL, commissioned naval officer, and physician assistant. Following consecutive deployments and multiple TBIs, David was one of the many warriors who took his own life. Repetitive TBI is linked to Post-Traumatic Stress Disorder (PTSD), Post-Concussion Syndrome (PCS) and mental illness. Each of these conditions increase the rate of suicidal ideation and completion.
A Community-Based Partnership (CBP) allows Odyssey Health’s scientific researchers across multiple disciplines to work side-by-side with the Metcalf Foundation’s community – many of whom have lived experience with TBI. The CBP assists in the development of Odyssey Health’s drug for treating TBI, specifically mild TBI (concussion). The CBP will include a needs assessment, clinical trial site planning, research intervention design, implementation, evaluation, and dissemination of community-level interventions. It is the CBP’s intent to enlist the support of the military community connected to The Metcalf Foundation with the research and scientists at Odyssey Health. This partnership will help make sure TBI interventions respond to the military community’s, particularly special operation forces, needs.
The CEO of the David R. Metcalf Invisible Wounds Foundation is Shannon Finn Connell, Ph.D. She is a U.S. Navy SEAL parent and serves as an advisor to the Navy SEAL Foundation focused on initiatives for warriors transitioning from military service to civilian life. Shannon is a former executive with SYSCO, Shell Oil, and Procter & Gamble. She obtained her Ph.D. in organizational development, researching design thinking as a problem-solving method in global organizational change initiatives. “Our foundation is active in coordinating research groups, finding funding for care, and bringing awareness to the devastating epidemic of TBI and suicide in our Naval Special Warfare and special operations forces communities. We work with military members, both active and retired, and their families, who face their own challenges as TBI and suicide effects the mental fortitude of loved ones. We are excited by a potential treatment for acute concussion. Highly trained warriors, like David, are medically qualified to take care of themselves and team members in training and combat. The Metcalf Foundation believes the nasal device care and temperature stability of Odyssey Health’s drug will give it a greater chance of success and promote its use in this community of war fighters.”
“Odyssey Health recognizes the need to have a partner associated with the US military that can not only give firsthand feedback about the effects of concussion but also help address logistics of treating the condition out in the field. Military medicine has different barriers to care than civilian medicine and we are excited to partner with the Metcalf Foundation to help us navigate and develop the first acute treatment for concussion,” commented Michael Redmond, Chief Executive Officer for Odyssey Health.
“I am excited to be working with The Metcalf Foundation and Odyssey Health to develop an acute treatment for brain injury which is absolutely needed for our military men and women. Understanding the environment and logistics to care for our Special Operations Forces will be critical for the clinical success of Odyssey’s treatment. I will be assisting the Metcalf Foundation in establishing community feedback needed from our special forces operators to properly design and implement Odyssey Health’s clinical trials,” commented Tim Szymanski, Vice Admiral (Retired) and former Deputy Commander of the United States Special Operations Command.
About Odyssey Health Inc. (formerly Odyssey Group International, Inc.)
Odyssey Health Inc. (OTC: ODYY) is a medical company with a focus on life-saving medical solutions. Odyssey's corporate mission is to create, acquire and develop distinct assets, intellectual property, and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity. For more information, visit the company’s website at www.odysseyhealthinc.com
We encourage our shareholders to visit our corporate social media accounts for updates:
https://twitter.com/OdysseyHealth1
https://www.facebook.com/odysseyhealthinc
https://www.linkedin.com/company/odysseyhealthinc
https://www.youtube.com/channel/UCsS--v0od_fYIBu2tvqmj9Q
About ONP-002
ONP-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, ONP-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that ONP-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, ONP-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete clinical trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Inquiries:
Odyssey Health
David R. Metcalf Invisible Wounds Foundation
Contact Details
Odyssey Health
Michael Redmond
View source version on newsdirect.com: https://newsdirect.com/news/odyssey-health-inc-forms-community-based-partnership-with-david-r-metcalf-foundation-for-military-concussion-research-371113475
